Actinogen Medical Limited (AU:ACW) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Actinogen Medical Limited has successfully completed an oversubscribed entitlement offer, raising $8.9 million to fund the progression of its XanaMIA Alzheimer’s disease trial and for general working capital. Shareholders demonstrated strong support with no shortfall in acceptances for shares, with new share trading to commence by June 6, 2024. The raised capital underscores shareholder confidence in the potential of Actinogen’s lead compounds in ongoing clinical trials.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.